Back in May 2021, Flagship Pioneering announced plans to develop as many as 100 Endless RNA (eRNA) products and drug programs over the next decade from the launch of Laronde, a platform company dedicated to achieving this goal. Three months later, Laronde has managed to secure as much as $440 million from a Series B financing round to support its mission further.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,